<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453075</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-001A-10F</org_study_id>
    <secondary_id>1lK2CX00536</secondary_id>
    <secondary_id>VAL115610</secondary_id>
    <nct_id>NCT01453075</nct_id>
    <nct_alias>NCT01525342</nct_alias>
  </id_info>
  <brief_title>Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)</brief_title>
  <official_title>Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and Herpes Simplex Virus 2 (HSV-2) Infection (Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effects of valacyclovir on patients who have
      hepatitis C and antibodies to herpes simplex type-2. Herpes simplex type 2 is a virus which
      causes genital herpes. Some persons with genital herpes have sores in their private areas but
      most persons do not have any symptoms at all. Valacyclovir is a medication which is commonly
      used to treat or prevent outbreaks of genital herpes. This medication is already approved by
      the Food and Drug Administration to treat genital herpes. Valacyclovir has not been approved
      to treat chronic hepatitis C.

      The study will take 16 weeks. Participants will be assigned to take either the study drug,
      valacyclovir, or a sugar pill that looks exactly like valacyclovir. The researchers and the
      persons participating will not know which medication they are receiving. Study visits will
      occur every two weeks and will take approximately 3-45 minutes. All study visits will occur
      at the G.V. Sonny Montgomery VA Medical Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study is a randomized, double-blinded, placebo-controlled, Phase II clinical trial.
      Participants will be recruited while attending regularly scheduled clinic appointments at the
      Jackson VA Medical Center. Baseline Visit. Participants will be randomized 1:1 in groups of
      10 to receive valacyclovir 1.5 gram orally twice daily or matching placebo. Enrolled
      participants will complete 12 weeks of assigned therapy.

      At the initial visit, participants will complete a short questionnaire detailing past
      medical/social history and relevant symptoms. Venipuncture will be performed to obtain
      samples for the laboratory tests. The baseline de-identified serum sample will be obtained
      from the clinical lab and stored in research-approved freezer space for future confirmation
      with the Biokit HSV-2 rapid assay. Follow-up visits will be scheduled at two-week intervals
      after baseline. At each visit, pill-count, compliance and tolerability of medications will be
      assessed using a short questionnaire. Venipuncture will be performed every four weeks (i.e.,
      at every other follow-up visit) to provide samples for the tests described below. Information
      from each study visit will be recorded into the chart by the PI or Research Assistant (RA)
      and entered into an encrypted database on a VA server. Laboratory Tests. HSV-2 infection will
      be confirmed by performing the Biokit HSV-2 rapid assay on the baseline stored serum sample
      using methods previously described in this proposal. Laboratory tests will include 1)
      complete blood count, comprehensive metabolic profile, and quantitative hepatitis C virus
      (HCV) RNA; and 2) Focus HerpeSelect HSV-1 Immunoglobulin G (IgG) for participants who were
      seronegative for HSV-1 at baseline. Patient's IL28-B genotype will also be assessed at
      baseline. The PI will review all laboratory parameters.

      Baseline characteristics between the groups will be compared using appropriate parametric
      tests. Analysis will be intention to treat with the inclusion of all subjects who were
      randomized to drug or placebo. The primary outcome is change in HCV viral load in the
      treatment group compared with placebo. Because the investigators are expecting a 0.5 log10
      decline in HCV viral load, the investigators will use one-sided parametric tests. All viral
      loads will be log10-transformed before analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of HSV-2 Suppression on HCV Viral Load.</measure>
    <time_frame>baseline; 12 weeks</time_frame>
    <description>Measure the change in serum HCV viral load at baseline and 12 weeks in patients who have chronic hepatitis C and HSV-2 infection who receive the 3 grams daily valacyclovir versus placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1: valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assigned patients will take 1.5 mg po valacyclovir twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assigned patients will receiving matching placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>Valacyclovir 1.5 mg po bid</description>
    <arm_group_label>Arm 1: valacyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo twice daily</description>
    <arm_group_label>Arm 2: placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documentation of chronic HCV infection with genotype testing and previous positive
             HerpeSelect HSV-2 IgG assay

        Exclusion Criteria:

          -  Antiherpes or immunomodulatory therapy during the past 30 days

          -  HIV or chronic hepatitis B infection

          -  Decompensated liver disease (ascites, hepatic encephalopathy, coagulopathy,
             jaundice/icterus)

          -  Creatinine clearance &lt; 50 ml/min.

          -  Female subject who is pregnant or nursing

          -  Gastrointestinal disorder which might result in malabsorption of valacyclovir

          -  History of erythema multiforme major, thrombotic thrombocytopenia purpura or hemolytic
             uremic syndrome

          -  Therapy for hepatitis C in the previous 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary J Burton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <results_first_submitted>June 13, 2016</results_first_submitted>
  <results_first_submitted_qc>September 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2016</results_first_posted>
  <last_update_submitted>September 30, 2016</last_update_submitted>
  <last_update_submitted_qc>September 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>herpes simplex type 2</keyword>
  <keyword>veterans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Valacyclovir</title>
          <description>Assigned patients will take 1.5 mg po valacyclovir twice daily
Valacyclovir: Valacyclovir 1.5 mg po bid</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Placebo</title>
          <description>Assigned patients will receiving matching placebo twice daily
Placebo: Matching placebo twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Valacyclovir</title>
          <description>Assigned patients will take 1.5 mg po valacyclovir twice daily
Valacyclovir: Valacyclovir 1.5 mg po bid</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Placebo</title>
          <description>Assigned patients will receiving matching placebo twice daily
Placebo: Matching placebo twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="3.5"/>
                    <measurement group_id="B2" value="58.8" spread="3.5"/>
                    <measurement group_id="B3" value="58.8" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of HSV-2 Suppression on HCV Viral Load.</title>
        <description>Measure the change in serum HCV viral load at baseline and 12 weeks in patients who have chronic hepatitis C and HSV-2 infection who receive the 3 grams daily valacyclovir versus placebo</description>
        <time_frame>baseline; 12 weeks</time_frame>
        <population>Analyzed patients who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Valacyclovir</title>
            <description>Assigned patients will take 1.5 mg po valacyclovir twice daily
Valacyclovir: Valacyclovir 1.5 mg po bid</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Assigned patients will receiving matching placebo twice daily
Placebo: Matching placebo twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of HSV-2 Suppression on HCV Viral Load.</title>
          <description>Measure the change in serum HCV viral load at baseline and 12 weeks in patients who have chronic hepatitis C and HSV-2 infection who receive the 3 grams daily valacyclovir versus placebo</description>
          <population>Analyzed patients who completed study</population>
          <units>log(IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" spread=".104"/>
                    <measurement group_id="O2" value=".03" spread=".75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Valacyclovir</title>
          <description>Assigned patients will take 1.5 mg po valacyclovir twice daily
Valacyclovir: Valacyclovir 1.5 mg po bid</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Placebo</title>
          <description>Assigned patients will receiving matching placebo twice daily
Placebo: Matching placebo twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Jane Burton</name_or_title>
      <organization>VA ORD</organization>
      <phone>6013624471 ext 1251</phone>
      <email>mary.burton2@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

